• 10 Dec 2024
• Admin
• News Article

Max Foundation & Novartis Expand Access to PNH Treatment

The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, announced it will expand its collaboration with Novartis to include Fabhalta (iptacopan), providing access to innovative treatment in low resource countries for paroxysmal nocturnal hemoglobinuria (PNH), a rare and debilitating blood disease that causes red blood cells to break apart.

We are thrilled to expand our reach to include people living with PNH in low-resource countries access to an innovative treatment for this life-threatening condition,” said Pat Garcia-Gonzalez, CEO of Max. This collaboration reaffirms the deeply shared value of health equity for both organizations by making the latest treatment approved for the disease available at no cost, fulfilling our mission to accelerate health equity and enabling people to live with dignity and hope.

PNH is caused by a genetic flaw that affects how red blood cells and platelets work. Only about 6 per 1 million people are diagnosed with it each year. People with PNH have sudden symptoms, including fatigue, weakness, increased heart rate, or shortness of breath, triggered by stressors like physical exertion or infection. During these episodes, red blood cells are broken down earlier than they should be, which causes patients to pass dark-coloured urine. If PNH isn’t treated, it can cause anaemia, chronic kidney disease, or blood clots.

For more than 20 years, Novartis has successfully partnered with The Max Foundation to advance health equity by providing access to our innovative oncology medicines. Together, we have reached more than 100,000 patients by now, delivering sustainable and profound impact on communities around the globe. Novartis is proud to further expand our strong partnership, thereby accelerating early access for PNH patients in need, said Lutz Hegemann, president, global health at Novartis.

The programme will initially focus on identifying partner physicians ready to treat PNH and creating access pathways into 53 countries in Sub-Saharan Africa, Latin America, the Caribbean, and Southeast Asia and Asia Pacific. In addition to medication access, Max is seeking to collaborate with medical experts to strengthen health systems by providing education and training, identifying other potential collaborators in low- and middle-income countries, building capacity at medical institutions and facilitating conversations and partnership engagement to expand access to treatment.

Max and Novartis have collaborated to improve access to innovative medicines since 2001.  Starting with access to medicines for chronic myeloid leukaemia and gastrointestinal stromal tumours, the collaboration has expanded to include advanced breast cancer and multiple rare diseases.  Novartis is a member of Max’s Humanitarian Partnership for Access to Critical Treatments (Humanitarian PACT), a collaboration among professional, nonprofit, and commercial organizations that share the commitment of the foundation to increase global access to treatment, care, and support for people living with cancer and other critical illnesses. Members of the Humanitarian PACT agree to invest resources and/or their unique organizational knowledge and capabilities to support the expansion of Max’s proven treatment access model.

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 27 years, Max has pioneered practical, scalable, high-quality solutions to bring lifesaving treatments and patient-centred health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries.